A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
Adigweme I, Yisa M, Ooko M, Akpalu E, Bruce A, Donkor S, Jarju LB, Danso B, Mendy A, Jeffries D, Segonds-Pichon A, Njie A, Crooke S, El-Badry E, Johnstone H, Royals M, Goodson JL, Prausnitz MR, McAllister DV, Rota PA, Henry S, Clarke E
- DOI
- 10.1016/S0140-6736(24)00532-4
- Record issued
- 2026-08-16
- Engine
- 7.39.0
- Exported
- 2026-09-21
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/f05c3b4e-8ead-4098-b1f6-90ffb2927f6d is authoritative.
How this rating was calculated
- ClaimsUnsupported claim (uncorroborated)−0.5★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- No reported statistical tests were found to recompute.
- No data or code availability links were detected to verify.
- 01Conclusion not supported by the paper’s own evidence
The MRV-MNP is expected to have improved thermostability, facilitating vaccine administration beyond the end of the cold chain.
“The MRV-MNPs are expected to have improved thermostability, facilitating vaccine administration beyond the end of the cold chain.”
IntroductionFind in source - 02Efficacy rests on an unvalidated surrogate endpoint
The primary efficacy claim is based on immunogenicity endpoints (seroconversion rates and geometric mean antibody concentrations) as surrogates for protection against measles and rubella. While the paper states that serum neutralising antibodies are the gold-standard correlates of protection, it does not provide validated evidence linking these surrogates to clinical outcomes, nor does it demonstrate target engagement at the tested dose beyond the immunogenicity readouts themselves.
“Serum neutralising antibodies are considered to be the gold-standard correlate of protection for both vaccines, although the data linking immunogenicity and effectiveness are scarce.”
- 03Treatment effect not shown to be clinically meaningful
The primary reported effect is the seroconversion rate in infants (93% for measles and 100% for rubella) following MRV-MNP administration. While these rates are high, the paper does not anchor them to a minimal clinically important difference or explicitly establish clinical meaningfulness beyond stating they are comparable to published rates. The effect size is presented descriptively without a formal statistical comparison to a threshold for clinical benefit.
“The measles seroconversion rate of 93% in infants who had the vaccine delivered by MNP is comparable to the rates reported in the published literature following subcutaneous delivery of the vaccine.”
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted and transparently reported phase 1/2 clinical trial of a measles-rubella vaccine microneedle patch. The paper demonstrates strong scientific premise, rigorous design, clear ethical approvals, and appropriate descriptive statistical analysis. Minor reporting gaps (outlier handling, explicit reporting guideline, and a few copyedit issues) do not undermine the overall robustness.
Both reviewers independently scored all eight dimensions and agreed on every status; no divergence required reconciliation. The statistics verification component checked 0 tests due to coverage limitations (no test statistics with df or effect estimates with CIs were machine-verifiable), so statistical correctness is not independently confirmed. The citation check found no retracted or unresolved references. The claim audit flagged one unsupported claim about thermostability.
Numerical inconsistencies
None foundValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
Checked — nothing surfaced.
Overstated conclusions
3 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Conclusions not supported by the paper’s own evidenceAssessed
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
5 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).
- unsupportedReviewer 1The MRV-MNP is expected to have improved thermostability, facilitating vaccine administration beyond the end of the cold chain.The paper does not present any data on thermostability; this is an expectation, not a finding.Evidence: No thermostability data are presented in the paper.
“The MRV-MNPs are expected to have improved thermostability, facilitating vaccine administration beyond the end of the cold chain.”
IntroductionFind in source - supportedReviewers 1, 2The MRV-MNP was well tolerated and safe in adults, toddlers, and infants.The safety data presented (no related severe or serious adverse events, all local reactions mild) support this claim.Evidence: Safety outcomes reported in Results: no related severe or serious adverse events; all local reactions mild.
“The safety and immunogenicity data support the accelerated development of the MRV-MNP.”
AbstractFind in source - supportedReviewers 1, 2The immunogenicity of the MRV when administered by MNP was similar to its immunogenicity when administered subcutaneously.Seroconversion rates and GMCs were comparable between groups, with overlapping confidence intervals.Evidence: Table 4 shows similar seroconversion rates and GMC ratios with CIs overlapping 1.
“In infants, 93% (52/56; 95% CI 83·0–97·2) seroconverted to measles and 100% (58/58; 93·8–100) seroconverted to rubella following MRV-MNP administration, while 90% (52/58; 79·2–95·2) and 100% (59/59; 93·9–100) seroconverted to measles and rubella respectively, following MRV-SC.”
AbstractFind in source - supportedReviewers 1, 2These are the first data demonstrating directly that MNPs are viable for the delivery of vaccines to children and infants.The paper states this is the first trial of MNP in children, and the results support viability.Evidence: The trial provides the first data on MNP use in children and infants.
“These are the first data demonstrating directly that MNPs are viable for the delivery of vaccines to children and infants.”
IntroductionFind in source - supportedReviewer 2The results support the accelerated development of the MRV-MNP.Given the positive safety and immunogenicity findings, this conclusion is reasonable.Evidence: The safety and immunogenicity data are presented in the results.
“The safety and immunogenicity data support the accelerated development of the MRV-MNP.”
AbstractFind in source
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary efficacy claim is based on immunogenicity endpoints (seroconversion rates and geometric mean antibody concentrations) as surrogates for protection against measles and rubella. While the paper states that serum neutralising antibodies are the gold-standard correlates of protection, it does not provide validated evidence linking these surrogates to clinical outcomes, nor does it demonstrate target engagement at the tested dose beyond the immunogenicity readouts themselves.
“Serum neutralising antibodies are considered to be the gold-standard correlate of protection for both vaccines, although the data linking immunogenicity and effectiveness are scarce.”
- INADEQUATEEffect sizeThe primary reported effect is the seroconversion rate in infants (93% for measles and 100% for rubella) following MRV-MNP administration. While these rates are high, the paper does not anchor them to a minimal clinically important difference or explicitly establish clinical meaningfulness beyond stating they are comparable to published rates. The effect size is presented descriptively without a formal statistical comparison to a threshold for clinical benefit.
“The measles seroconversion rate of 93% in infants who had the vaccine delivered by MNP is comparable to the rates reported in the published literature following subcutaneous delivery of the vaccine.”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
None foundRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
Checked — nothing surfaced.
The introduction and 'Research in context' section cite prior studies on microneedle patches for influenza and Japanese encephalitis vaccines, and note the absence of data in children and for MRV. The rationale linking the need for improved vaccine coverage to MNP technology is well articulated. Limitations of prior research (e.g., no pediatric data) are explicitly identified and addressed by this trial.
“Five studies have been conducted in adults examining the administration of the inactivated influenza vaccine by dissolvable (n=2) or solid (n=3) microneedle patches.”
“There are no published data on the use of MNPs to deliver vaccines to children or infants (the key target group) or on the use of the technology to administer the measles and rubella vaccine (MRV).”
“Indeed, the Vaccine Innovation Prioritization Strategy, a consortium including WHO, UNICEF, and Gavi, the Vaccine Alliance, recently ranked the development of MNP as the highest global priority for achieving equity of vaccine coverage in low-income and middle-income countries.”
“Five studies have been conducted in adults examining the administration of the inactivated influenza vaccine by dissolvable (n=2) or solid (n=3) microneedle patches.”
“There are no published data on the use of MNPs to deliver vaccines to children or infants (the key target group) or on the use of the technology to administer the measles and rubella vaccine (MRV).”
“Indeed, the Vaccine Innovation Prioritization Strategy, a consortium including WHO, UNICEF, and Gavi, the Vaccine Alliance, recently ranked the development of MNP as the highest global priority for achieving equity of vaccine coverage in low-income and middle-income countries.”
Randomization method (predefined scheme by independent statistician) and unit (individual participant) are reported. Blinding is comprehensive (double-dummy, masked staff, participants, and assessors). Sample size is justified descriptively (probability of detecting safety events) rather than by a formal power calculation, which is appropriate for a phase 1/2 trial. Inclusion/exclusion criteria are prespecified, and the analysis populations (safety and immunogenicity) are clearly defined. Outlier handling is not explicitly discussed, but the analysis population definitions address missing data.
“Random allocation was done using a predefined randomisation scheme generated by an independent statistician.”
“Staff administering the study interventions, participants, parents, and study staff assessing trial endpoints were masked to treatment allocation.”
“Random allocation was done using a predefined randomisation scheme generated by an independent statistician.”
“Staff administering the study interventions, participants, parents, and study staff assessing trial endpoints were masked to treatment allocation.”
Sex is reported for all cohorts, and both sexes are included, so sex justification is not applicable. Age, weight, length, and weight-for-length Z scores are reported in Table 1. Species/strain and housing conditions are not applicable as this is a human trial. Demographics (age, sex, ethnicity, tribe) are adequately reported.
“Male | 30 (50%) | 30 (50%) | 26 (43%) | 25 (42%)”
“25 (83%) of 30 participants in the MRV-MNP group and 13 (87%) of 15 participants in the placebo-MNP group were male; 5 (17%) of 30 and 2 (13%) of 15 participants were female, respectively.”
“To be eligible, participants had to be healthy according to the inclusion and exclusion criteria defined for the trial (appendix pp 3–5).”
The study was approved by The Gambia Government/MRC Joint Ethics Committee (with protocol number), the London School of Hygiene & Tropical Medicine Research Ethics Committee, and the Gambian Medicines Control Agency. Written informed consent was obtained from participants or parents/guardians. Regulatory compliance is implied through the approvals and adherence to Good Manufacturing Practice.
“The study was approved by The Gambia Government/MRC Joint Ethics Committee (LEO 22420), the London School of Hygiene & Tropical Medicine Research Ethics Committee, and the Gambian Medicines Control Agency.”
“All participants or parents or guardians of participants provided written informed consent.”
“The study was approved by The Gambia Government/MRC Joint Ethics Committee (LEO 22420), the London School of Hygiene & Tropical Medicine Research Ethics Committee, and the Gambian Medicines Control Agency.”
“All participants or parents or guardians of participants provided written informed consent.”
The MRV-MNP (Micron Biomedical) and MRV-SC (Serum Institute of India) are named with their viral content and excipients. The placebo is specified. Statistical software (R version 4.2.2) is identified. Antibodies, cell lines, and mycoplasma testing are not applicable as this is a clinical trial without wet-lab assays.
“Both the MRV-MNP (Micron Biomedical, Atlanta, GA, USA) and the single 0·5 mL dose of the MRV for subcutaneous injection (Serum Institute of India, Pune, India) contained not less than 1000 cell culture infectious dose (CCID 50 ) of the live-attenuated Edmonston-Zagreb measles virus and not less than 1000 CCID 50 of the live-attenuated Wistar RA 27/3 rubella virus.”
“Analysis was conducted in R version 4.2.2.”
“Both the MRV-MNP (Micron Biomedical, Atlanta, GA, USA) and the single 0·5 mL dose of the MRV for subcutaneous injection (Serum Institute of India, Pune, India) contained not less than 1000 cell culture infectious dose (CCID 50 ) of the live-attenuated Edmonston-Zagreb measles virus and not less than 1000 CCID 50 of the live-attenuated Wistar RA 27/3 rubella virus.”
“Analysis was conducted in R version 4.2.2.”
Statistical tests are named (Wilson score, Newcombe, Student's t on log-transformed data). Assumptions (log-normality) are stated and verified. Exact p-values are not reported; instead, the analysis is descriptive with 95% CIs, which is appropriate for this phase 1/2 trial. Effect sizes (GMC ratios, differences in proportions) are reported with 95% CIs. Software is identified. Data presentation includes per-group n, CIs, and figures. Mathematical plausibility checks on reported percentages and counts did not reveal inconsistencies.
“CIs around proportions were calculated using the Wilson's score method without continuity correction, and CIs around difference in proportions were calculated using the Newcombe method without continuity correction.”
“GMC (95% CI) | 572·8 (450·1 to 729·1) | 566·9 (448·8 to 716·1) | 1·01 (0·73 to 1·41)”
“The trial was designed to provide descriptive data on the safety and immunogenicity of the MRV-MNP and comparator data on MRV-SC to guide product development decisions, rather than by a power calculation to test a formal statistical hypothesis.”
“CIs around proportions were calculated using the Wilson's score method without continuity correction, and CIs around difference in proportions were calculated using the Newcombe method without continuity correction.”
“GMC (95% CI) | 572·8 (450·1 to 729·1) | 566·9 (448·8 to 716·1) | 1·01 (0·73 to 1·41)”
“The trial was designed to provide descriptive data on the safety and immunogenicity of the MRV-MNP and comparator data on MRV-SC to guide product development decisions, rather than by a power calculation to test a formal statistical hypothesis.”
The data availability statement is concrete: it specifies that individual participant data will be shared after de-identification, available from 3 months to 3 years after publication, and that access requires a scientifically sound proposal and a data access agreement. This meets the criteria for managed access. Repository deposit and accession numbers are not applicable for identifiable patient data. Code sharing is not applicable as no bespoke code is mentioned.
“Individual participant data will be shared after de-identification and made available from 3 months after publication until 3 years after publication. Clinical documents, including the study protocol, statistical analysis plan, and informed consent form will be available immediately after publication. Researchers who provide a scientifically sound proposal to the corresponding author and sign a data access agreement will receive access to individual participant data.”
“Individual participant data will be shared after de-identification and made available from 3 months after publication until 3 years after publication.”
“Researchers who provide a scientifically sound proposal to the corresponding author and sign a data access agreement will receive access to individual participant data.”
The trial is registered with PACTR202008836432905. Methods are comprehensive. Limitations are explicitly discussed (small sample size, descriptive analysis, restrictive eligibility). Conclusions are appropriately cautious, noting the need for larger trials. Funding and COI statements are provided. A reporting guideline (CONSORT) is not explicitly mentioned, but the paper follows clinical trial reporting standards.
“The trial was registered with the Pan African Clinical Trials Registry, PACTR202008836432905.”
“The trial had several limitations which predominantly reflect its early phase design. Although it is the largest trial of MNP conducted to date and the only trial in children, the samples size was relatively small.”
“SH, DVM, MRP, and MR are employees of, or affiliated with, Micron Biomedical. All other authors declare no competing interests.”
“The trial was registered with the Pan African Clinical Trials Registry, PACTR202008836432905.”
“The trial had several limitations which predominantly reflect its early phase design. Although it is the largest trial of MNP conducted to date and the only trial in children, the samples size was relatively small.”
“SH, DVM, MRP, and MR are employees of, or affiliated with, Micron Biomedical. All other authors declare no competing interests.”
Registration stated in text, but no registry ID was detected. No reporting guideline cited.
Broken references and links
None found · partly checkedReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.
Checked 28 references by DOI: 24 verified — 4 no DOI (shown, not verified).
- NO DOIMeasles vaccines: WHO position paper - April 2017No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIVaccine Innovation Prioritisation Strategy (VIPS)No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIMeasles-rubella microarray patch (MR-MAP) target product profileNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe immunological basis for immunization series: module 11: rubella: updateNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
Copyediting
4 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 4 minor suggestions below.
4 copyedit issues flagged: mostly consistency, typo, clarity.
- MINORtypoMethods, Randomisation and masking“apprearance”→ appearanceTypographical error in the word 'appearance'.
- MINORconsistencyResults, Toddler cohort“59 toddlers (98%) had at least one of the 203 unsolicited adverse events reported following MRV-MNP”→ Ensure the number of events (203) is consistent with the appendix table.The number of events may need cross-checking with the appendix.
- MINORclarityDiscussion“the samples size was relatively small”→ the sample size was relatively smallGrammatical error: 'samples' should be 'sample'.
- MINORconsistencyResults, paragraph 1“89 adults, 196 toddlers, and 161 infants were screened”→ Verify screening numbers against appendix.Screening numbers are not shown in a flow diagram for adults; ensure consistency.
The published work is robust and well-reported; an informed reader should weigh the descriptive (non-hypothesis-testing) nature of the analysis and the small sample sizes as inherent limitations. The unsupported thermostability claim in the discussion warrants a correction or tempering, and minor copyedit issues (typos, consistency) could be addressed in an erratum. No major rigor gaps that would require re-analysis were identified.
- 1.HIGHrigorIn the Discussion, either add supporting data for the claim that 'The MRV-MNP is expected to have improved thermostability, facilitating vaccine administration beyond the end of the cold chain' or remove/temper it to reflect that it is an expectation, not a finding.The claim audit flagged this as unsupported; presenting an expectation as a finding could mislead readers and reviewers.
- 2.HIGHreportingAdd an explicit statement in the Methods or Acknowledgments that the trial was reported in accordance with CONSORT guidelines.Both reviewers noted the absence of an explicit reporting guideline, which is a standard expectation for clinical trials.
- 3.HIGHrigorIn the Methods/Statistical analysis section, add a statement on how outliers were handled (or that none were excluded) and clarify the handling of missing data for the day 180 immunogenicity population.Both reviewers flagged outlier handling as 'reported_but_inadequate'; clarifying this strengthens the analysis population definition.
- 4.MEDIUMreportingAdd a CONSORT flow diagram for the adult cohort to match the toddler and infant cohorts, and verify the screening numbers (89 adults, 196 toddlers, 161 infants) against the appendix.The copyedit pass flagged inconsistency in screening numbers; a flow diagram would improve transparency and consistency.
- 5.MEDIUMcopyeditFix the typo 'apprearance' to 'appearance' in Methods, Randomisation and masking.Minor typographical error that should be corrected for professionalism.
- 6.MEDIUMcopyeditFix the grammatical error 'the samples size was relatively small' to 'the sample size was relatively small' in the Discussion.Grammatical error that detracts from clarity.
- 7.MEDIUMreportingVerify the number of unsolicited adverse events (203) in the toddler cohort against the appendix table and correct if inconsistent.The copyedit pass flagged potential inconsistency; ensuring accuracy is important for safety data.
- 8.MEDIUMreportingSpecify the version of the statistical analysis plan and whether it was finalized before unblinding, and note any amendments in the trial registration.Reviewers suggested this to enhance transparency and reproducibility.
- 9.MEDIUMreportingClarify the role of the independent data monitoring committee in the age de-escalation process, including predefined stopping rules.Reviewers noted this would strengthen the description of safety oversight.
- 10.MEDIUMreportingProvide more detail on the randomization scheme (e.g., block size, stratification factors) in the appendix.Reviewers suggested this to improve reproducibility of the randomization process.
- 11.LOWreportingIn the Discussion, explicitly address the potential for unblinding due to local reactions at the MNP site, which could introduce bias.Reviewer suggestion to acknowledge a potential source of bias in a double-blind trial.
- 12.LOWreportingAdd a note on the generalizability of the findings given the single-center design and specific population (The Gambia).Reviewers suggested this to contextualize the external validity of the results.
- 13.LOWreportingConsider reporting exact p-values for key comparisons, even if descriptive, to facilitate future meta-analyses.Reviewer suggestion to enhance the utility of the reported data for secondary analyses.
- 14.LOWreportingAdd a statement on whether the trial was conducted in accordance with ICH-GCP guidelines.Reviewer suggestion to explicitly confirm regulatory compliance.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.